Table 2 Myocardial infarction at baseline and CHD risk during follow-up by baseline LTL in the GENEDIAB cohort

3.76 (1.12–17.08)

0.03

7.84 (1.65–54.57)

0.008

2.85 (0.93–10.64)

0.07

4.56 (1.15–22.61)

0.03

1.32 (0.28–6.86)

0.72

1.72 (0.28–12.36)

0.55

0.60 (0.36–0.99)

0.05

0.31 (0.14–0.62)

0.0007

2.55 (1.26–5.57)

0.009

3.06 (1.37–7.43)

0.006

3.14 (1.39–7.70)

0.005

1.56 (0.87–2.85)

0.14

1.84 (0.91–3.84)

0.09

1.63 (0.80–3.39)

0.18

1.63 (0.78–3.63)

0.20

1.66 (0.72–4.08)

0.24

1.92 (0.81–4.91)

0.14

0.76 (0.58– 1.01)

0.06

0.71 (0.52–0.96)

0.03

0.73 (0.54–0.98)

0.03